

Description:

pLX302 was developed by TRC. Key features of this vector include:

(i) CMV promoters for robust and consistent ORF expression;
(ii) high viral titers with inclusion of cPPT and WPRE elements;
(iii) Selectable marker expression (*PAC* that confer Puromycin resistance);
(iv) V5 epitope sequence tagged to the C-terminal end of each ORF.

Additionally, this vector contain a Gateway cassette encoding the Chloromphenicol resistance gene and the ccdB topoisomerase poison, and the pLKO vector backbone encoding Amp/Carb resistance. The ccdB gene product is toxic to DH5alpha bacteria. As a result, DH5α cannot be used to amplify this destination vector in preparation of the starting materials for LR reactions. Whereas in selecting for the intended recombination products in LR reactions, one needs to use DH5α, as unrecombined destination vector cannot propagate in DH5α.

Note: One Shot® ccdB Survival™ 2 T1R Competent Cells (Cat. No. A10460) are needed for amplifying ccdB-bearing pLX vectors.